Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496830 · ClinicalTrials.gov registry record
SPINCOMS Biomarker Study
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 161
- Enrollment target
NCT04496830: Completed study, sponsored by Washington University School of Medicine.
NCT04496830 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04496830 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
To determine if biomarker-based CSF testing is reliably detecting differences between patients with Multiple Sclerosis (MS), different MS-subtypes, and other central nervous system (CNS) diseases. This study will also look to identify biomarkers that could be used for the prediction, at the time of diagnosis, of the future disease clinical course and response to therapy. The SOMAscan assay will be used for CSF samples analysis.
Primary Outcome
CSF-biomarker-predicted outcomes against measured NeurEx-based outcomes, considering a Bonferroni-adjusted significance level 0.05/3 = 0.017 (to adjust for 3 tests).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2023-11-24 |
What the finished NCT04496830 record still lists
NCT04496830 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04496830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04496830 about?
NCT04496830 is a clinical study titled "SPINCOMS Biomarker Study". To determine if biomarker-based CSF testing is reliably detecting differences between patients with Multiple Sclerosis (MS), different MS-subtypes, and other central nervous system (CNS) diseases. This study will also look to identify biomarkers that could be used for the prediction, at the time of ...
What is the current status of trial NCT04496830?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2020-06-15. Estimated completion is 2023-11-24.
Who is sponsoring clinical trial NCT04496830?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI